A Fower

Test-retest reliability of plasma biomarkers and digital cognitive metrics at clinically meaningful timescales

Abstract Background Digital cognitive testing and plasma biomarkers have emerged as key players for population screening and measuring drug efficacy in clinical trials for Alzheimer’s Disease (AD). Understanding test-retest reliability of these tools is essential to estimate mean...